India's Ranbaxy gains; U.S. drug regulator approves generic version of Novartis drug

MUMBAI (Reuters) - India’s Ranbaxy Laboratories rose 5.8 percent in early trading after the U.S. Food and Drug Administration said on Thursday it had approved the company’s generic version of Novartis AG’s blood pressure drug Diovan. Investors say current market…

Source: India’s Ranbaxy gains; U.S. drug regulator approves generic version of Novartis drug